Bay Colony Advisory Group Inc d b a Bay Colony Advisors Purchases Shares of 14,397 Inotiv, Inc. (NASDAQ:NOTV)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Inotiv, Inc. (NASDAQ:NOTV) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,397 shares of the company’s stock, valued at approximately $60,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors owned about 0.06% of Inotiv as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Nkcfo LLC purchased a new stake in Inotiv in the fourth quarter valued at $476,000. Vantage Point Financial LLC purchased a new stake in Inotiv in the fourth quarter valued at $1,393,000. Thurston Springer Miller Herd & Titak Inc. boosted its holdings in Inotiv by 612.5% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 127,257 shares of the company’s stock valued at $527,000 after purchasing an additional 109,397 shares during the last quarter. Calamos Advisors LLC purchased a new stake in Inotiv in the fourth quarter valued at $275,000. Finally, Geode Capital Management LLC boosted its holdings in Inotiv by 7.7% in the third quarter. Geode Capital Management LLC now owns 250,895 shares of the company’s stock valued at $427,000 after purchasing an additional 18,039 shares during the last quarter. 18.17% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Inotiv

In related news, Director David Landman purchased 23,529 shares of the firm’s stock in a transaction that occurred on Thursday, December 19th. The shares were purchased at an average cost of $4.25 per share, with a total value of $99,998.25. Following the purchase, the director now owns 176,851 shares of the company’s stock, valued at $751,616.75. This represents a 15.35 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert Jr. Leasure sold 73,617 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $3.82, for a total transaction of $281,216.94. Following the completion of the transaction, the chief executive officer now directly owns 956,592 shares in the company, valued at $3,654,181.44. This represents a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 61,029 shares of company stock valued at $274,448 and have sold 108,311 shares valued at $425,330. Corporate insiders own 7.80% of the company’s stock.

Inotiv Trading Down 1.5 %

NOTV stock opened at $2.62 on Friday. The company’s 50-day simple moving average is $4.04 and its 200-day simple moving average is $3.07. The company has a quick ratio of 1.28, a current ratio of 1.57 and a debt-to-equity ratio of 2.31. Inotiv, Inc. has a 52-week low of $1.23 and a 52-week high of $11.42. The firm has a market cap of $88.34 million, a P/E ratio of -0.57 and a beta of 3.77.

Inotiv (NASDAQ:NOTV) last posted its earnings results on Wednesday, February 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.10). Inotiv had a negative return on equity of 15.41% and a negative net margin of 25.40%. As a group, equities analysts forecast that Inotiv, Inc. will post -0.79 EPS for the current fiscal year.

Inotiv Company Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.